BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a $4.00 price target by stock analysts at HC Wainwright in a report released on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 238.98% from the stock’s current price.
A number of other research analysts have also weighed in on BLRX. Roth Capital set a $3.00 price target on shares of BioLineRx and gave the company a “buy” rating in a research report on Wednesday. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the stock a “buy” rating in a report on Tuesday. Zacks Investment Research upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. began coverage on shares of BioLineRx in a report on Friday, August 4th. They set an “outperform” rating and a $3.00 price objective for the company. Finally, ValuEngine upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $2.59.
BioLineRx (NASDAQ:BLRX) opened at 1.18 on Wednesday. The company has a 50-day moving average of $0.91 and a 200-day moving average of $0.96. The firm’s market cap is $72.90 million. BioLineRx has a 52 week low of $0.79 and a 52 week high of $1.42.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). Equities research analysts forecast that BioLineRx will post ($0.24) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “BioLineRx Ltd. (NASDAQ:BLRX) Given a $4.00 Price Target at HC Wainwright” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/08/09/biolinerx-ltd-nasdaqblrx-given-a-4-00-price-target-at-hc-wainwright.html.
Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC increased its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Renaissance Technologies LLC bought a new stake in BioLineRx during the first quarter worth about $126,000. Benchmark Capital Advisors increased its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. KCG Holdings Inc. increased its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC bought a new stake in BioLineRx during the first quarter worth about $3,018,000. Institutional investors and hedge funds own 34.91% of the company’s stock.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
